(NASDAQ: VTYX) Ventyx Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Ventyx Biosciences's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast VTYX's revenue for 2027 to be $3,362,553,166, with the lowest VTYX revenue forecast at $185,402,147, and the highest VTYX revenue forecast at $6,539,704,186. On average, 2 Wall Street analysts forecast VTYX's revenue for 2028 to be $17,802,884,604, with the lowest VTYX revenue forecast at $584,729,848, and the highest VTYX revenue forecast at $35,021,039,360.
In 2029, VTYX is forecast to generate $22,711,406,440 in revenue, with the lowest revenue forecast at $2,923,649,238 and the highest revenue forecast at $42,499,163,643.